Since we have shown through our study that some of the characteristics found in PsA are present also in psoriasis patients without PsA (circulating complement, anti-LL37carb antibodies, GM-CSF), longitudinal follow-up of psoriasis patients with antibody reactivity to LL37 and higher complement and GM-CSF levels may be highly informative about the evolution of psoriasis into a more systemic inflammation that eventually develop to PsA. This evidence concerns the gene CSF2 and psoriasis.